Letrozole versus tamoxifen for ovulation induction in non-polycystic ovarian syndrome anovulatory infertile females

Eman Ahmed Kishk

Department of Obstetrics and Gynecology, Faculty of Medicine, Suez Canal University, Egypt

ABSTRACT

**Background:** Anovulation is the most common cause for infertility, different oral agents are used for induction of ovulation, tamoxifen may be effective as letrozole in this era.

**Objective:** The aim of this study was to compare the effectiveness of tamoxifen and letrozole in terms of ovulation induction outcomes in non PCOS anovulatory patients.

**Patients and Methods:** This randomized single blinded clinical trial was conducted among a total of 120 patients with anovulatory infertility that were randomized to one of two treatment arms: Letrozole group and Tamoxifen group. The treatment was continued for three consecutive cycles. Main outcome measures were number of follicles ≥ 18mm, endometrial thickness and ovulation rate. Secondary outcomes measures were cumulative pregnancy rate and spontaneous abortion rates.

**Results:** Mean number of mature follicles ≥ 18 mm was statistically significantly higher in Tamoxifen group (1.9 ± 1.1) when compared to Letrozole group (1.5 ± 0.9) with *p*-value=0.03. Also, endometrial thickness was significantly different between both groups; as it was higher in Tamoxifen group (8.2 ± 1.6 mm versus 7.08 ± 2.4 mm) in Letrozole group (*p*-value=0.02). No significant difference was reported between both groups as regarding ovulation rate, pregnancy rate and spontaneous abortion rate, ovulation rate was 73.3% with Letrozole and 63.3% with Tamoxifen (*P* =0.3), cumulative pregnancy rate was 30% with Letrozole group and 23.3% with Tamoxifen group (*p*=0.5) and spontaneous abortion rate was 3.3% in Letrozole group and 5% in Tamoxifen group (*p*=0.9).

**Conclusion:** Tamoxifen drug has comparable ovulation induction outcomes to letrozole with very low costs and side effects. Tamoxifen could be considered suitable for ovulation induction in developing countries.

**Key Words:** Anovulation, infertility, letrozole, ovulation induction, tamoxifen

INTRODUCTION

Anovulation is the most common cause for infertility; it represents 20-25% of all cases of infertility[1]. Tamoxifen is a triphenylethylene that closely resembles clomiphene citrate (CC). The use of tamoxifen for ovulation induction has been the subject of clinical investigation since the early 1970s. Klopper and Hall were the first to describe successful results with tamoxifen for the induction of ovulation in women suffering from secondary amenorrhea[2].

Previous studies reported the value of tamoxifen in corpus luteum insufficiency and inadequate cervical mucus secretion[3]. Previous clinical trials with tamoxifen demonstrated that the overall ovulation and pregnancy rates were similar or superior to CC and does not appear to have an adverse impact on the endometrium[4].

Another oral agent that has been recently introduced to the era of ovulation is letrozole. Aromatase inhibitors were first used in ovulation induction in 2001[5-7]. Letrozole is a third-generation aromatase inhibitor blocks the conversion of androgens to estrogens in the ovarian follicles, peripheral tissues, and in the brain, this leads to fall in circulating and local estrogens and release the hypothalamopituitary axis from the negative feedback of estrogens. Thus, there is a surge in follicle stimulating hormone (FSH) release, which results in follicular growth. Since, the feedback mechanism is intact; normal follicular growth, selection of dominant follicle, and atresia of smaller growing follicle occurs; and thereby facilitating monofollicular growth and ovulation[8].

Aromatase inhibitors increases intraovarian androgens thereby increases the follicular sensitivity to FSH. Androgen has a role in early follicular developments by
augmenting FSH receptors and stimulating insulin-like growth factor (IGF)-1; FSH and IGF-I act synergistically to promote follicular growth\(^{[9]}\).

Most of the previous studies have compared the effectiveness of ovulation induction agents regardless of the costs which is an important issue in developing countries.

**AIM OF THE WORK**

In the present study, we aimed to compare effectiveness of letrozole as a relatively expensive oral agent and tamoxifen as a cheap agent in terms of ovulation induction outcomes.

**PATIENTS AND METHODS**

This randomized single blinded clinical trial was conducted at Suez Canal University Hospital, the study protocol was approved by the ethics committee and an informed written consent was obtained from all participants.

Inclusion criteria were infertile women aged 20-35 years, BMI < 30 kg/m², with either primary or secondary type of infertility and eligible for ovulation induction after exclusion of male factor by normal semenogram, normal hormonal profile [follicle-stimulating hormone (FSH), luteinizing hormone (LH), thyroid-stimulating hormone (TSH) and prolactin hormone], normal uterine cavity and patent fallopian tubes based on hysterosalpingography (HSG) or laparoscopy and no history of ovulation induction in the previous 3 months.

Required sample size was estimated based on power of study of 90% and \( \alpha \) error of 0.05\(^{[10]}\). Every patient was followed for 3 consecutive cycles.

**Randomization and treatment arms:**

Women (n= 124) were randomized into two groups, group A included 62 patients received letrozole while group B included another 62 patients received tamoxifen. A total of 120 patients had completed the study (60 patients in each group), as 4 cases were lost during follow up period (Figure 1).

Fig. 1: Flow chart of the studied population
Transvaginal ultrasonography (TVS) was done on the 3rd day of the menstrual cycle (for exclusion of any ovarian cysts), induction of ovulation in letrozole group was started with letrozole 2.5 mg tablet (Femara®, Novartis CO., Egypt) once daily and tamoxifen 10 mg tablet (Tamofen®, Al-Amarya CO., Egypt) once daily in tamoxifen group started from the 3rd day to the 7th day of the cycle.

If ovulation failed to occur with the initial dose of either drug, the daily dosage was increased in letrozole group by 2.5 mg increment in subsequent cycle to 5 and 7.5 mg in subsequent cycles and in tamoxifen group by 10 mg increment in subsequent cycle to 20 and 30 mg. Treatment has been stopped if they became pregnant or if patient did not ovulate with maximum dose and these patients were labeled as treatment resistant or failed to concept after three months despite ovulation and these patients were labeled as treatment failure. Also, if intolerable symptoms as depression, severe headache or dizziness, pain and vision changes had occurred treatment was discontinued.

Serial folliculometry was done by TVS starting day 8 of menstrual cycle till at least one follicle reached ≥ 18 mm. Endometrial thickness was assessed prior to Human Chorionic Gonadotrophin (HCG) administration (10000 IU) (Epifassi®, EPICO CO., Egypt) followed by intercourse after 24 to 36 hours. Serum beta human chorionic gonadotropin (B-hCG) was checked after two weeks to confirm pregnancy. Gestational sac was assessed by transvaginal ultrasonography at 6th week of gestation.

Outcome measures:

Main outcome measures were number of follicles ≥18 mm, endometrial thickness and ovulation rate. Secondary outcome measures were clinical pregnancy rates and spontaneous abortions rates.

STATISTICAL ANALYSIS

Data were processed using SPSS version 15 (SPSS Inc., Chicago, IL, USA). Quantities data were expressed as means ± SD and qualitative data were expressed as numbers and percentages. Student's T-test was used to test significance of difference for quantitative variables while Chi-square and fisher's exact tests were used to test significance for qualitative variables. A probability value (p-value) < 0.05 was considered statistically significant.

RESULTS

Table 1 shows that patients of both groups were matched as regarding age, body mass index (BMI), duration and type of infertility. Mean age was 28.72 ± 5.5 years in letrozole group and 26.1 ± 5.8 years in tamoxifen group (p-value > 0.05). BMI was 24.9 ± 3.2 and 25.4 ± 2.9 kg/m² in letrozole and tamoxifen respectively, with no significant difference. Mean duration of infertility was 4.6 ± 1.9 years in letrozole group and 5.2 ± 2.4 years in tamoxifen group (p-value > 0.05), 90% of the letrozole group and 86.7% of tamoxifen group were classified as primary infertility (p-value > 0.05).

As regarding primary outcome measures, tamoxifen showed significantly higher endometrial thickness (8.2 mm versus 7.08 mm) compared to letrozole group (p-value = 0.02). Number of follicles ≥ 18 mm was significantly higher with tamoxifen group (1.9 mm versus 1.5 mm among letrozole group patients; p-value = 0.03). No significant difference was reported between both groups as regarding ovulation rate, pregnancy rate, spontaneous abortion rate, treatment resistance rate and treatment failure rate. Ovulation rate was 73.3% with letrozole and 63.3% with tamoxifen. Cumulative pregnancy rate was 30% with letrozole and 23.3% with tamoxifen group. None of patients of letrozole and tamoxifen groups have multiple pregnancies (Table 2).

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Letrozole group (n=60)</th>
<th>Tamoxifen group (n=60)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (Years)</td>
<td>Mean ± SD</td>
<td>28.72 ± 5.5</td>
<td>26.1 ± 5.8</td>
</tr>
<tr>
<td>BMI (kg/m2)</td>
<td>Mean ± SD</td>
<td>24.9±3.2</td>
<td>25.4±2.9</td>
</tr>
<tr>
<td>Primary infertility</td>
<td>54 90%</td>
<td>52 86.7%</td>
<td></td>
</tr>
<tr>
<td>Secondary infertility</td>
<td>6 10%</td>
<td>8 13.3%</td>
<td></td>
</tr>
<tr>
<td>Duration of infertility</td>
<td>Mean ± SD</td>
<td>4.6 ± 1.9</td>
<td>5.2 ± 2.4</td>
</tr>
</tbody>
</table>

NS: No statistically significant difference
**DISCUSSION**

This study compares two oral ovulation induction agents (Letrozole and Tamoxifen) among non-PCOS anovulatory women. To the best of our knowledge, few studies have compared both letrozole and tamoxifen as ovulation induction agents as most of the available studies compare them to the most widely used ovulation induction agent clomiphene citrate.

The present study has shown that both letrozole and tamoxifen have comparable ovulation and pregnancy rates (73.3% versus 63.3% and 30% versus 23.3%) with no statistically significant difference. Previous studies have shown similar rate of pregnancy as for letrozole. Hendawy and colleagues have shown that pregnancy rate among PCOS women with use of letrozole to be 33%. Other previous results showed consistent findings. Elnashar et al. reported an ovulation rate of 54.6% and pregnancy rate of 25% with letrozole induction in clomiphene citrate-resistant women with PCOS and Ganesh et al. reported the ovulation rate of 79.3% and the pregnancy rate of 23.39% with letrozole.

We have found that endometrial thickness and number of follicles were significantly higher with the use of tamoxifen. Letrozole- unlike CC- has shorter half-life and thus has lower peripheral anti-estrogen effect with little effect on endometrial thickness. Consistently Abu Hashim et al. reported that endometrial thickness on 14 cycles had no significant increase in the letrozole group. Unlike the present study, Seyedoshohadaei et al. has reported higher endometrial thickness with letrozole than tamoxifen but with no statistically significant difference.

Most of the available reports on tamoxifen as oral ovulation induction agents have shown consistent findings with the present study. In accordance with the present findings, Dhaliwal et al. has reported ovulation rate of 68% and pregnancy rate of 16.5%. They have also reported significant increase in both ovulation and pregnancy rate with doubling Tamoxifen daily dosage from 40 mg to 80 mg.

An earlier study by Williamson et al. reported an ovulation rate of 81% which is even higher than the rate reported in the present study. In another study by Messinis et al. the ovulation rate was 76.08% that is similar to the present finding. Tamoxifen improves folliculogenesis process by blocking oestradiol-binding sites on the hypothalamic-pituitary axis and preventing the negative feedback effect of oestradiol, so increasing gonadotrophin secretion improves function.

---

**Table 2: Outcome measures among both groups:**

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Letrozole group (n=60)</th>
<th>Tamoxifen group (n=60)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of follicles ≥ 18 mm Mean ± SD</td>
<td>1.5 ± 0.9</td>
<td>1.9 ± 1.1</td>
<td>0.03*</td>
</tr>
<tr>
<td>Endometrial thickness (mm) Mean ± SD</td>
<td>7.08 ± 2.4</td>
<td>8.2 ± 1.6</td>
<td>0.02*</td>
</tr>
<tr>
<td></td>
<td>6 – 10</td>
<td>7 – 12</td>
<td></td>
</tr>
<tr>
<td>Ovulation rate</td>
<td>44 (73.3%)</td>
<td>38 (63.3%)</td>
<td>0.3 (NS)</td>
</tr>
<tr>
<td>Pregnancy rate</td>
<td>18 (30%)</td>
<td>14 (23.3%)</td>
<td>0.5 (NS)</td>
</tr>
<tr>
<td>Spontaneous abortion rate</td>
<td>2 (3.3%)</td>
<td>3 (5%)</td>
<td>0.9 (NS)</td>
</tr>
<tr>
<td>Treatment resistance</td>
<td>11 (18.3%)</td>
<td>14 (23.3%)</td>
<td>0.6 (NS)</td>
</tr>
<tr>
<td>Treatment failure</td>
<td>5 (8.3%)</td>
<td>8 (13.3%)</td>
<td>0.6 (NS)</td>
</tr>
</tbody>
</table>

*Statistically significant difference
NS: Not statistically significant difference
of the corpus luteum, in addition to its beneficial effects on the cervical mucus and endometrium receptivity\textsuperscript{[3]}. So, tamoxifen may be used to increase pregnancy rate.

The present study has shown that both tamoxifen and letrozole are tolerable drugs and not associated with serious side effects. Consistently Williamson \textit{et al.}\textsuperscript{[19]} and Klopper \textit{et al.}\textsuperscript{[2]} did report mild side-effects in the form of headache and mild ovarian enlargement. Also, more recently and in accordance with the present study, Dhaliwal \textit{et al.}\textsuperscript{[1]} and Seyyedoshohadaei \textit{et al.}\textsuperscript{[14]} didn’t report any serious side effects with tamoxifen.

One of the most important advantages of both agents is very low rates of multiple pregnancies\textsuperscript{[1, 12, 21]}. Consistent with the available reports, we have reported no cases of multiple pregnancies with either drug.

CONCLUSION

Both letrozole and tamoxifen are effective ovulation induction agents with comparable ovulation and pregnancy rates and rare incidence of multiple pregnancies and few tolerable side effects. Further researches should be directed toward the clinical and routine use of tamoxifen in field of ovulation induction due to appreciable advantages as high pregnancy and ovulation rates and low multiple pregnancy rates, tolerable side effects and low price. The major limitation of the present study is that we have followed patients for only three consecutive cycles.

CONFLICT OF INTEREST

There are no conflict of interests.

REFERENCES


15. Ganesh A, Goswami SK, Chattopadhyay R, Chaudhury K, Chakravarty B. Comparison

16. Elnashar A, Fouad H, Eldosoky M, Saeid N. Letrozole induction of ovulation in women with clomiphene citrate-resistant polycystic ovary syndrome may not depend on the period of infertility, the body mass index, or the luteinizing hormone/follicle-stimulating hormone ratio. Fertil Steril 2006; 85: 511-513


